GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

Home
/
update
/
details

Approval Granted: Applied DNA's TR8(TM) Pharmacogenomic (PGx) Testing Service Receives Green Light from New York State Department of Health

NextEdge Admin

14 Jun 2024

2 min 32 sec

Applied DNA Sciences, Inc. has achieved a significant milestone with the approval of its TR8™ PGx pharmacogenomic testing service by the New York State Department of Health (NYSDOH). This approval underscores the Company's commitment to advancing personalized medicine through innovative DNA technologies.

The TR8™ PGx service, offered through Applied DNA's clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), analyzes 120 genetic targets across more than 30 genes. This comprehensive analysis provides healthcare providers with crucial insights into how patients may respond to various medications used in treating conditions such as cardiovascular issues, oncology, psychiatric disorders, infectious diseases, and pain management. Administered through a simple cheek swab, this testing service empowers healthcare professionals to tailor medication choices based on each patient's unique genetic makeup.

With NYSDOH approval, Applied DNA is poised to address the growing demand for pharmacogenomic testing in New York State, a market ripe with potential. The Company is actively engaging in discussions with enterprise customers, healthcare networks, and concierge physicians to integrate PGx testing into their services. By partnering with employers, healthcare systems, and large-scale enterprises, Applied DNA aims to establish a strong presence in the market and contribute to improved patient outcomes and reduced healthcare costs.

Dr. James A. Hayward, President and CEO of Applied DNA, highlights the rigorous standards set by NYSDOH and emphasizes the Company's commitment to advancing personalized medicine. By providing scalable and cost-effective genetic testing solutions, Applied DNA aims to empower healthcare providers and patients alike, facilitating more informed treatment decisions and ultimately promoting healthier lives.